Kowdley KV, et al. - The clinicians evaluated the benefit of obeticholic acid (OCA) in the absence of UDCA, which was relevant for patients who were intolerant of UDCA and at higher risk of disease progression. Alkaline phosphatase (ALP) and other biochemical markers predictive of improved long-term clinical outcomes were significantly improved by OCA monotherapy. Pruritus increased dose-dependently with OCA treatment. They observed biochemical improvements through 6 years of open-label extension (OLE) treatment.